Amplify Treat Test and AdvaGERMETF
13F holders, Q3 2024 (September 30)1holders −10
0new positions
11sold out
$19.16avg. 13F price*
At the end of Q3 2024, 1 institutions reported holding Amplify Treat Test and Adva (GERM) in their 13F filings, down 10 from Q2 2024. 0 opened new positions and 11 sold out. The largest holder was IFP Advisors, Inc ($4K).
- Company
- Amplify Treat Test and Adva
- CUSIP
- 032108581
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 11 | $1.4M |
All 13F filers, Q2 2024 → Q3 2024: 78,176 shares sold, net −78,176 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| IFP Advisors, Inc | 0.00% | No change | 200 | $4K |
"% of holder's portfolio" is GERM's weight in each manager's 13F, not the share of Amplify Treat Test and Adva the manager owns.